AstraZeneca wins EU approval of Axanum for CV prevention in those at gastric risk
This article was originally published in Scrip
Executive Summary
AstraZeneca’s fixed-dose combination therapy, Axanum (esomeprazole plus low dose aspirin), has received positive agreement for approval in 23 European Union member countries and in Norway for the prevention of cardiovascular (CV) events in high-risk patients who require daily low-dose aspirin treatment but are also at risk of gastric ulcers.